Eli Lilly’s stock dives as Mounjaro and Zepbound sales miss, but Citi says buy
Eli Lilly’s stock heads for biggest selloff in 24 years after sales of anti-obesity drugs Mounjaro and Zepbound came up well ...
Eli Lilly’s Bad Quarter Doesn’t Change the Long-Term Math on Obesity Bonanza
Eli Lilly had a bad quarter, with sales of GLP-1 drugs Mounjaro and Zepbound missing analyst estimates. The disappointment led to a [15% plunge in Lilly’s shares]( ...
Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings miss
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...